mTOR-inhibiting pharmacotherapy for the treatment of non-infectious uveitis: a systematic review protocol.

about

mTOR-inhibiting pharmacotherapy for the treatment of non-infectious uveitis: a systematic review protocol.

Item

http://www.wikidata.org/entity/Q55260506

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

mTOR-inhibiting pharmacotherap ...... a systematic review protocol.

@en

mTOR-inhibiting pharmacotherap ...... a systematic review protocol.

@nl

type

Item

label

mTOR-inhibiting pharmacotherap ...... a systematic review protocol.

@en

mTOR-inhibiting pharmacotherap ...... a systematic review protocol.

@nl

prefLabel

mTOR-inhibiting pharmacotherap ...... a systematic review protocol.

@en

mTOR-inhibiting pharmacotherap ...... a systematic review protocol.

@nl

P1476

mTOR-inhibiting pharmacotherap ...... a systematic review protocol.

@en

P2093

David J Moore

http://www.w3.org/2001/XMLSchema#string

Joshua Blair

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

The mTOR signalling pathway in human cancer

Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop

Heterogeneity of primary outcome measures used in clinical trials of treatments for intermediate, posterior, and panuveitis

Quantifying heterogeneity in a meta-analysis

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Prospective evaluation of visual acuity assessment: a comparison of snellen versus ETDRS charts in clinical practice (An AOS Thesis).

Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.

Pharmacotherapy for uveitis: current management and emerging therapy.

Systemic therapies for inflammatory eye disease: past, present and future

mTOR Inhibition Attenuates Dextran Sulfate Sodium-Induced Colitis by Suppressing T Cell Proliferation and Balancing TH1/TH17/Treg Profile

P2888

s13643-018-0745-2

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1186/S13643-018-0745-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Alastair K. Denniston

Philip I. Murray

Robert J Barry

P5008

ScienceSource

P577

2018-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1104496888

http://www.w3.org/2001/XMLSchema#string

P698

29885659

http://www.w3.org/2001/XMLSchema#string

P921

P932

5994244

http://www.w3.org/2001/XMLSchema#string